SEC Form 4 · accession 0001993684-26-000006

Immunome Inc. · IMNM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Jul 23, 2026

Accepted (ET)

Jul 27, 2026 · 4:10 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001472012

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 23, 2026	A	38,250	$0.00	A	60,250	D
Common Stock^F2	holding	—	—		—	1,000	I	As Custodian for Child 1
Common Stock^F2	holding	—	—		—	1,000	I	As Custodian for Child 2
Common Stock^F2	holding	—	—		—	1,000	I	As Custodian for Child 3

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F3	$22.01	Jul 23, 2026	A	76,500	A	—	Jul 22, 2036	Common Stock	76,500	76,500	D

F1Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F2The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.
F325% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.